Biocon reports 5% revenue growth to ₹164.7bn

Biocon Limited reported consolidated total income of ₹164,699 million for FY25, a 5% increase year-over-year.

Biosimilars contributed 58% of operational revenue, followed by Research Services at 23% and Generics at 19%. Profit attributable to shareholders was ₹10,133 million.

The company recommended a final dividend of ₹0.50 per equity share for FY25.